Reports
Sale
Global Self Amplifying RNA Vaccines Market Report, Forecast: By Route of Administration: Intradermal, Intranasal, Intramuscular, Others; By Application: Influenza, Rabies, HIV-1, COVID-19, Respiratory Syncytial Virus (RSV), Ebola, Others; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis; Supplier Landscape; 2024-2032
Self Amplifying RNA Vaccines Market Size
The global self amplifying RNA vaccines market was valued at USD 5.8 billion in 2023 driven by increasing investment in healthcare research and development across the globe. The market is anticipated to grow at a CAGR of 13.1% during the forecast period 2024-2032 to reach a value of USD 9.6 billion by 2032.
Self Amplifying RNA Vaccines Market Outlook
- The market is driven by the increasing number of self-amplifying RNA (saRNA) vaccine candidates to fight against various infectious and viral conditions.
- The market is witnessing heavy investments by research institutes, biopharmaceutical companies, and governments, to explore wider applications of saRNA vaccines.
- The increasing approvals by the regulatory authorities are playing a crucial role in market development, thereby, boosting market growth.
Self Amplifying RNA Vaccines Market Overview
Self-amplifying RNA (saRNA) vaccines use a self-replicating RNA platform to generate immune responses in the body. RNA vaccines work by triggering the immune system to defend against specific pathogens, using messenger RNA instead of inactivated viruses. Self-amplifying RNA vaccines are a specialized type of RNA vaccine that allows the RNA to replicate within the host cells. This self-amplification process leads to a strong immune response and higher levels of protein production. saRNA vaccine produces enhanced immunogenicity, and lower doses are required due to its self-amplifying nature and rapid production. This continues to drive the development of saRNA vaccine technology.
Self Amplifying RNA Vaccines Market Growth Drivers
FDA Clearances Being Instrumental in Rising Market Demand
The market growth is driven by the evolving regulatory landscape that is allowing high-efficacy vaccines and medications in the market to address unmet needs for a wider section of the population. For instance, in April 2024, Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutic development, received approval from the U.S. Food and Drug Administration for its Investigational New Drug application concerning RAG-01. This innovative saRNA treatment is expected to treat non-muscle invasive bladder cancer. This FDA approval is poised to commence clinical trials in several other regions along with the United States, bolstering market growth as regulatory approvals and clinical trials play a vital role in adding credibility to new drugs.
Additionally, the world’s first saRNA vaccine ARCT-154 was approved by the Japanese regulatory authorities in Japan in November 2023. This approval has given access to a new weapon to healthcare providers, through which the prevention of infectious diseases, and management of chronic diseases such as cancer will be made easier than ever. This approval marked a significant milestone as the first saRNA vaccine to be registered in the world.
Self Amplifying RNA Vac cines Market Trends
The market is witnessing several trends and developments to improve the global current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Technological Advancements | The market is witnessing technological advancements in the diagnostic domain. Innovations in lipid nanoparticle delivery systems are playing a crucial role in market development as they enable stability and enhance efficacy along with the safety profile of vaccinations. |
| Rising focus on Next-Generation Vaccines | The growing interest in next-generation vaccines, including saRNA vaccines, is driving extensive research and development activities, collectively exploring wider applications for saRNA in other domains, boosting market demand and development. |
| Increasing Investment and Funding | The key players in the healthcare domain, government and healthcare institutions are investing to support the development of saRNA vaccines and bring effective treatments for viruses and infectious conditions. |
| Increasing Adoption Post COVID-19 Outbreak | The market is witnessing a rising number of saRNA vaccine candidates being developed for various infectious diseases, including COVID-19, influenza, and other viral infections. |
Self Amplifying RNA Vaccines Market Segmentation
Market Breakup by Route of Administration
- Intradermal
- Intranasal
- Intramuscular
- Others
Market Breakup by Application
- Influenza
- Rabies
- HIV-1
- COVID-19
- Respiratory Syncytial Virus (RSV)
- Ebola
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Self Amplifying RNA Vaccines Market Share
Market Segmentation Based on Application to Witness Significant Growth
Based on application, the market report includes influenza, rabies, HIV-1, COVID-19, respiratory syncytial virus (RSV), and Ebola, among others. Historically, the COVID-19 segment has had a significant share of the market, driven by the advent of an unforeseen pandemic which triggered an urgent demand for effective vaccines, and led to the quick development of RNA-based vaccines globally. The market segment is backed by heavy investments by the government and several key players in the market.
Self Amplifying RNA Vaccines Market Analysis by Region
Based on region, the market is divided into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Out of these, North America is the leading market due to the presence of global players in the region. The market dominance can be attributed to factors technical innovations as well as product launches.
Europe, with the presence of prominent academic institutions, holds a significant market share. In addition, the Asia Pacific region is expected to witness substantial growth in the forecast period. The rapid growth can be attributed to rising investments in improving the healthcare infrastructure to boost research and development initiatives related to the market. Countries like India, Japan and China are expected to emerge as key regional players in the Asia Pacific market.
Leading players in the Self Amplifying RNA Vaccines Market
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis along with strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer is a global leader in developing and producing vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company played a pivotal role in the COVID-19 pandemic. The company partnered with BioNTech to study and develop COVID-19 mRNA vaccine candidates during the pandemic and delivered millions of vaccines.
Gennova Biopharmaceuticals Limited
The company is headquartered in Pune, India. Gennova is a biotechnology company focused on the research, development, production, and commercialization of bio-therapeutics and vaccines to address life-threatening diseases across various indications.
Arcturus Therapeutics, Inc.
It is an American RNA medicines biotechnology company focused on finding, developing, and delivering treatments for rare diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
VLP Therapeutics Japan, LLC
VLP Therapeutics Japan, LLC specialises in developing innovative vaccines and therapeutics using their proprietary Virus-Like Particle (VLP) technology. Their portfolio includes cutting-edge vaccines for infectious diseases such as dengue fever, malaria, and COVID-19, aimed at providing effective and long-lasting immunity with enhanced safety profiles.
CSL Limited
It is an Australian biotechnology company focused on the research, development, and commercialisation of products that treat and prevent serious human medical conditions. The company portfolio includes blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.
Other key players in the market include TriLink BioTechnologies, ImmunityBio, Inc., Gritstone bio, Inc., and eTheRNA Immunotherapies NV.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Route of Administration |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Self Amplifying RNA Vaccines Market
- What was the global self amplifying RNA vaccines market value in 2023?
- What is the global self amplifying RNA vaccines market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on application?
- How is the market segmented based on the route of administration?
- What are the major factors aiding the self amplifying RNA vaccines market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major self amplifying RNA vaccines market trends?
- Which route of administration is expected to dominate the market?
- Which application will dominate the market share?
- Who are the key players involved in the self amplifying RNA vaccines market?
- What is the patent landscape of the market?
- How many clinical trials are being conducted for self amplifying RNA vaccines?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Self Amplifying RNA Vaccines Market Overview
3.1 Global Self Amplifying RNA Vaccines Market Historical Value (2017-2023)
3.2 Global Self Amplifying RNA Vaccines Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Self Amplifying RNA Vaccines Market Landscape*
5.1 Global Self Amplifying RNA Vaccines Market: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Self Amplifying RNA Vaccines Market: Product Landscape
5.2.1 Analysis by Route of Administration
5.2.2 Analysis by Application
6 Global Self Amplifying RNA Vaccines Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Self Amplifying RNA Vaccines Market Segmentation (2017-2032)
7.1 Global Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
7.1.1 Market Overview
7.1.2 Intradermal
7.1.3 Intranasal
7.1.4 Intramuscular
7.1.5 Others
7.2 Global Self Amplifying RNA Vaccines Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Influenza
7.2.3 Rabies
7.2.4 HIV-1
7.2.5 COVID-19
7.2.6 Respiratory Syncytial Virus (RSV)
7.2.7 Ebola
7.2.8 Others
7.3 Global Self Amplifying RNA Vaccines Market (2017-2032) by Region
7.3.1 Market Overview
7.3.2 North America
7.3.3 Europe
7.3.4 Asia Pacific
7.3.5 Latin America
7.3.6 Middle East and Africa
8 North America Self Amplifying RNA Vaccines Market (2017-2032)
8.1 North America Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
8.1.1 Market Overview
8.1.2 Intradermal
8.1.3 Intranasal
8.1.4 Intramuscular
8.1.5 Others
8.2 North America Self Amplifying RNA Vaccines Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Influenza
8.2.3 Rabies
8.2.4 HIV-1
8.2.5 COVID-19
8.2.6 Respiratory Syncytial Virus (RSV)
8.2.7 Ebola
8.2.8 Others
8.3 North America Self Amplifying RNA Vaccines Market (2017-2032) by Country
8.3.1 United States of America
8.3.2 Canada
9 Europe Self Amplifying RNA Vaccines Market (2017-2032)
9.1 Europe Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
9.1.1 Market Overview
9.1.2 Intradermal
9.1.3 Intranasal
9.1.4 Intramuscular
9.1.5 Others
9.2 Europe Self Amplifying RNA Vaccines Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Influenza
9.2.3 Rabies
9.2.4 HIV-1
9.2.5 COVID-19
9.2.6 Respiratory Syncytial Virus (RSV)
9.2.7 Ebola
9.2.8 Others
9.3 Europe Self Amplifying RNA Vaccines Market (2017-2032) by Country
9.3.1 United Kingdom
9.3.2 Germany
9.3.3 France
9.3.4 Italy
9.3.5 Others
10 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032)
10.1 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
10.1.1 Market Overview
10.1.2 Intradermal
10.1.3 Intranasal
10.1.4 Intramuscular
10.1.5 Others
10.2 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Influenza
10.2.3 Rabies
10.2.4 HIV-1
10.2.5 COVID-19
10.2.6 Respiratory Syncytial Virus (RSV)
10.2.7 Ebola
10.2.8 Others
10.3 Asia Pacific Self Amplifying RNA Vaccines Market (2017-2032) by Country
10.3.1 China
10.3.2 Japan
10.3.3 India
10.3.4 ASEAN
10.3.5 Australia
10.3.6 Others
11 Latin America Self Amplifying RNA Vaccines Market (2017-2032)
11.1 Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
11.1.1 Market Overview
11.1.2 Intradermal
11.1.3 Intranasal
11.1.4 Intramuscular
11.1.5 Others
11.2 Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Influenza
11.2.3 Rabies
11.2.4 HIV-1
11.2.5 COVID-19
11.2.6 Respiratory Syncytial Virus (RSV)
11.2.7 Ebola
11.2.8 Others
11.3 Latin America Self Amplifying RNA Vaccines Market (2017-2032) by Country
11.3.1 Brazil
11.3.2 Argentina
11.3.3 Mexico
11.3.4 Others
12 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032)
12.1 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Route of Administration
12.1.1 Market Overview
12.1.2 Intradermal
12.1.3 Intranasal
12.1.4 Intramuscular
12.1.5 Others
12.2 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Application
12.2.1 Market Overview
12.2.2 Influenza
12.2.3 Rabies
12.2.4 HIV-1
12.2.5 COVID-19
12.2.6 Respiratory Syncytial Virus (RSV)
12.2.7 Ebola
12.2.8 Others
12.3 Middle East and Africa Self Amplifying RNA Vaccines Market (2017-2032) by Country
12.3.1 Saudi Arabia
12.3.2 United Arab Emirates
12.3.3 Nigeria
12.3.4 South Africa
12.3.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trial Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Grants Analysis
16.1 Analysis by Year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Funding and Investment Analysis
17.1 Analysis by Funding Instances
17.2 Analysis by Type of Funding
17.3 Analysis by Funding Amount
17.4 Analysis by Leading Players
17.5 Analysis by Leading Investors
17.6 Analysis by Geography
18 Strategic Initiatives
18.1 Analysis by Partnership Instances
18.2 Analysis by Type of Partnership and Collaborations
18.3 Analysis by Joint Ventures
18.4 Analysis by Leading Players
18.5 Analysis by Geography
19 Supplier Landscape
19.1 Market Share Analysis, By Region (Top 5 Companies)
19.1.1 Market Share Analysis: Global
19.1.2 Market Share Analysis: North America
19.1.3 Market Share Analysis: Europe
19.1.4 Market Share Analysis: Asia Pacific
19.1.5 Market Share Analysis: Others
19.2 Gennova Biopharmaceuticals Limited
19.2.1 Financial Analysis
19.2.2 Product Portfolio
19.2.3 Demographic Reach and Achievements
19.2.4 Company News and Development
19.2.5 Certifications
19.3 Arcturus Therapeutics, Inc.
19.3.1 Financial Analysis
19.3.2 Product Portfolio
19.3.3 Demographic Reach and Achievements
19.3.4 Company News and Development
19.3.5 Certifications
19.4 VLP Therapeutics Japan, LLC
19.4.1 Financial Analysis
19.4.2 Product Portfolio
19.4.3 Demographic Reach and Achievements
19.4.4 Company News and Development
19.4.5 Certifications
19.5 CSL Limited
19.5.1 Financial Analysis
19.5.2 Product Portfolio
19.5.3 Demographic Reach and Achievements
19.5.4 Company News and Development
19.5.5 Certifications
19.6 TriLink BioTechnologies
19.6.1 Financial Analysis
19.6.2 Product Portfolio
19.6.3 Demographic Reach and Achievements
19.6.4 Company News and Development
19.6.5 Certifications
19.7 ImmunityBio, Inc.
19.7.1 Financial Analysis
19.7.2 Product Portfolio
19.7.3 Demographic Reach and Achievements
19.7.4 Company News and Development
19.7.5 Certifications
19.8 Pfizer Inc.
19.8.1 Financial Analysis
19.8.2 Product Portfolio
19.8.3 Demographic Reach and Achievements
19.8.4 Company News and Development
19.8.5 Certifications
19.9 Gritstone bio, Inc.
19.9.1 Financial Analysis
19.9.2 Product Portfolio
19.9.3 Demographic Reach and Achievements
19.9.4 Company News and Development
19.9.5 Certifications
19.10 eTheRNA Immunotherapies NV
19.10.1 Financial Analysis
19.10.2 Product Portfolio
19.10.3 Demographic Reach and Achievements
19.10.4 Company News and Development
19.10.5 Certifications
20 Global Self Amplifying RNA Vaccines Market – Distribution Model (Additional Insight)
20.1 Overview
20.2 Potential Distributors
20.3 Key Parameters for Distribution Partner Assessment
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER